Global Antimicrobial Resistance Trends in Group B Streptococcus Isolates From Pregnant Women: Systematic Review and Meta-Analysis

全球孕妇分离的B族链球菌抗菌药物耐药性趋势:系统评价和荟萃分析

阅读:1

Abstract

Maternal colonization with Group B Streptococcus (GBS) is associated with a high risk of serious infections during pregnancy. Also, the emerging resistance of GBS isolates to commonly used antibiotics has become a serious concern. This study aimed to provide a systematic review and meta-analysis of worldwide data on the prevalence of antimicrobial resistance of GBS in pregnant women to establish a better understanding of more effective antibiotic agents. A systematic literature search was performed in PubMed, Web of Science, and Scopus databases up to January 31, 2025. Statistical analysis was performed using the meta and metaphor packages in R, and sources of heterogeneity were evaluated using I(2). The potential for publication bias was explored using Egger's and Begg's tests. A total of 169 eligible studies were included. The highest rate of resistance was associated with tetracycline (77.8%), while the lowest rates were found for vancomycin (0.59%), penicillin (0.7%), ampicillin (1%), and cefazolin (1.34%). The global resistance rates to penicillin, erythromycin, vancomycin, and clindamycin exhibited a gradual increasing trend in the 2021-2024 periods compared with other periods. The results highlighted the low levels of resistance to ampicillin and penicillin for pregnant women without an allergy history and cefazolin and vancomycin for those with an allergy history. However, given the increasing resistance trends and the high prevalence of resistance to clindamycin and erythromycin, these antibiotics should be recommended after antibiotic susceptibility testing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。